Conference Overview

The Society for Neuro-Oncology (SNO), in collaboration with the American Society of Clinical Oncology (ASCO), present this year’s SNO/ASCO CNS Metastases Conference to be held August 13-15, 2026, at the Westin Copley Place in Boston, Massachusetts. The theme is From Moonshot to Groundshot: Transforming Science into Impact and the scientific content of this dynamic event includes outstanding keynote and plenary addresses on the complex and rapidly evolving area of CNS metastases.

 

The program is interdisciplinary, intentionally structured to connect discovery to clinical impact across the continuum of brain and leptomeningeal metastasis care. Sessions will address basic, translational, and clinical research defining CNS tropism and the metastatic microenvironment, highlighting advances in multidisciplinary treatment strategies, including precision neurosurgery, modern radiotherapy techniques such as stereotactic radiosurgery and FLASH, and the rational integration of systemic therapies. The agenda further examines topics which underscore the progression from scientific moonshots to ground-level changes in patient care. In addition, the latest work shown in selected scientific abstracts will be highlighted in oral presentations and the poster networking reception.

Some areas include:

·       CNS-active targeted agents and immunotherapies

·       device-based local therapies; tumor-treating fields

·       management of acute and long-term treatment-related toxicities

·       patient quality of life and survivorship

·       data-driven decision-making

As an adjunct to the cutting-edge multidisciplinary science that will be presented, we expect the conference in Boston will provide an outstanding and unparalleled forum for networking and socializing with like-minded colleagues from around the world who are focused on advancing CNS metastases research and patient care, as well as the opportunity to interact with exhibitors from SNO’s industry and non-profit partners.

Join us just prior to the conference for a complimentary Early Career Professionals and Young Investigators Workshop—an engaging opportunity to build essential skills, expand your professional network, and support your career development in neuro-oncology.

Conference Overview

The Society for Neuro-Oncology (SNO), in collaboration with the American Society of Clinical Oncology (ASCO), present this year’s SNO/ASCO CNS Metastases Conference to be held August 13-15, 2026, at the Westin Copley Place in Boston, Massachusetts. The theme is From Moonshot to Groundshot: Transforming Science into Impact and the scientific content of this dynamic event includes outstanding keynote and plenary addresses on the complex and rapidly evolving area of CNS metastases.

 

The program is interdisciplinary, intentionally structured to connect discovery to clinical impact across the continuum of brain and leptomeningeal metastasis care. Sessions will address basic, translational, and clinical research defining CNS tropism and the metastatic microenvironment, highlighting advances in multidisciplinary treatment strategies, including precision neurosurgery, modern radiotherapy techniques such as stereotactic radiosurgery and FLASH, and the rational integration of systemic therapies. The agenda further examines topics which underscore the progression from scientific moonshots to ground-level changes in patient care. In addition, the latest work shown in selected scientific abstracts will be highlighted in oral presentations and the poster networking reception.

Some areas include:

·       CNS-active targeted agents and immunotherapies

·       device-based local therapies; tumor-treating fields

·       management of acute and long-term treatment-related toxicities

·       patient quality of life and survivorship

·       data-driven decision-making

As an adjunct to the cutting-edge multidisciplinary science that will be presented, we expect the conference in Boston will provide an outstanding and unparalleled forum for networking and socializing with like-minded colleagues from around the world who are focused on advancing CNS metastases research and patient care, as well as the opportunity to interact with exhibitors from SNO’s industry and non-profit partners.

Join us just prior to the conference for a complimentary Early Career Professionals and Young Investigators Workshop—an engaging opportunity to build essential skills, expand your professional network, and support your career development in neuro-oncology.

ABSTRACT

SUBMISSION

BE A PRESENTER

The organizers of the SNO/ASCO Conference on CNS Metastases welcome the submission of original research and clinical findings

addressing CNS basic science research, translational research, and clinical trials. Previously presented (encore) or not yet presented clinical trial abstracts and trials in progress are welcome but must be identified as such in the submission process. All submissions are peer-reviewed and accepted abstracts are presented as oral talks or in-person posters. Electronic posters will be available online at the start of the Conference.

Deadline for submissions is Friday, March 27, 2026, 11:59 pm ET.  

Accepted abstracts will be published and indexed in Neuro-Oncology Advances.  

Planning Committee Leadership

Co-Chairs

Jona Hattangadi-Gluth, University of California, San Diego

Jarushka Naidoo, RCSI University of Medicine and Health Sciences


Co-Chairs Elect

Michelle Kim, University of Michigan

Sani Kizilbash, Mayo Clinic


Immediate Past Co-Chairs

Nancy Lin, Dana Farber Cancer Institute

Solmaz Sahebjam, Johns Hopkins University


Planning Committee 

Allison Betof Warner, Stanford University

Sasha Beyer, The Ohio State University Comprehensive Cancer Center

Mariza Daras, VCU Massey Cancer Center

Zeynep Eroglu, Moffitt Cancer Center

Isabella Glitza Oliva, University of Texas MD Anderson Cancer Center 

Katarzyna Jerzak, Sunnybrook Research Institute, University of Toronto

Nayan Lamba, Brigham and Women's Hospital

Michelle E. Melisko, University of California, San Francisco

Jing Li, University of Texas MD Anderson Cancer Center 

Seema Nagpal, Stanford University

Nancy Wang, Massachusetts General Hospital

Helena A. Yu, Memorial Sloan Kettering Cancer Center